Journal profile · Medicine-Hematology
Transplantation and Cellular Therapy
ISSN 2666-6375 · eISSN 2666-6367 · Elsevier
Transplantation and Cellular Therapy: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.12; fully open access; APC about USD 4,000; median 79 days to acceptance (101 articles, last 24 months); 217 articles a year; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Transplantation and Cellular Therapy, the official publication of the American Society for Transplantation and Cellular Therapy, is dedicated to the comprehensive development and advancement of the interdisciplinary field of hematopoietic cell transplantation (HCT) and cellular therapies. The Journal emphasizes excellence in clinical care and treatment outcomes through the promotion of standards, best practices, and evidence-based approaches in HCT and cellular therapy.The Journal focuses on current technology, groundbreaking research, and clinical applications in HCT and related cellular therapies. Committed to the rapid dissemination of basic, translational, and clinical research, Transplantation and Cellular Therapy publishes original research reports, practice guidelines, reviews, editorials, commentaries, and letters to the editor to advance scientific knowledge and inform both the medical community and the broader public.For further information and the most up to date journal policies, please review our Guide for Authors.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Hematology
Editor-in-chief Robert KorngoldPublisher website
Editorial board by country: none in mainland China; most named United States 81, Germany 6, Canada 6, United Arab Emirates 2, Japan 1 (100 members with a country) Editorial board ↗Publisher website ·
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Hematology | Zone 3 |
| Minor | Immunology | Zone 3 |
| Minor | Transplantation | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Hematology | Zone 2 |
| Minor | Immunology | Zone 3 |
| Minor | Transplantation | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Hematology | Zone 3 |
| Minor | Immunology | Zone 3 |
| Minor | Transplantation | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PubMedPublisher website
Other: Crossref
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.12LetPub ·
- Impact factor (publisher)
- 4.7Publisher website ·
- CiteScore 2026-06
- 8.1LetPub ·
- CiteScore (publisher)
- 8.1Publisher website ·
- SJR 2026-06
- 2.25LetPub ·
- SNIP 2026-06
- 1.32LetPub ·
- Self-citation rate
- 10.6%LetPub ·
- Share of gold OA articles
- 28.92%LetPub ·
Volume
- Articles per year
- 217LetPub ·
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
79 daysMedian, submission to acceptance · P25–P75 50 days – 107 days
- Acceptance to online
- median 6 days (101 articles)
- Submission to online
- median 87 days
- Sample
- 101 articles with submission and acceptance dates (873 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to first decision
- 3 daysPublisher website ·
- First decision after review
- 29 daysPublisher website ·
- Submission to acceptance
- 74 daysPublisher website ·
- Acceptance to publication
- 5 daysPublisher website ·
- Peer review
- Single-anonymous peer reviewPublisher website · model-extracted
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessLetPub
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | USD 4,000 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare8 items from the author guidelines
- Abstract
- 250–500 words
- Manuscript length
- ≤ 1,200 words
- Reference style
- AMA
- First submission
- Free format: the journal's layout is not required
- Highlights
- Required
- Graphical abstract
- Optional
- Cover letter
- Required
- Not considered
- Case Reports
Article types accepted2, with length limits
- letter to the editorications are written in the format of a letter to the editor (without any section headings) and should not exceed 1,200 words with a maximum of 1 table or figur…main text ≤ 1,200 words
- review articleis made, and revisions may be required. Review articles should be limited to no more than 5,000 words (exclusive of references)and no more than 80 references. C…main text ≤ 5,000 words
Policy excerpts from the journal's websiteAI use, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI in scientific writing
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Conflicts of interest Declaration of interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places:…
Source ↗Publisher website ·- Publication ethics Ethical considerations
Transplantation and Cellular Therapy considers research and publication misconduct to be a serious breach of ethics, and will take such actions as necessary to address such misconduct. Authors should refer to the Committee on Publication Ethics (COPE) and the International Committee of Medical Journal Editors for full information. Authors are also encouraged to visit Elsevier's Ethical Guidelines …
Source ↗Publisher website ·- License & copyright Copyright
All material in Transplantation and Cellular Therapy represents the opinions of the authors and does not reflect the opinions of the American Society for Transplantation and Cellular Therapy (ASTCT), Elsevier Inc., or the institutions with which the authors are affiliated. Authors submitting manuscripts do so with the understanding that, if accepted, copyright in the article, including the right t…
Source ↗Publisher website ·- Open access Open access options
Please visit our Open Access page for more information about open access publishing in this journal.
Source ↗Publisher website ·- Peer review Rapid Peer Review/Fast Track
Expedited review will be offered, on request, for articles falling within the scope of the topics suitable for Transplantation and Cellular Therapy that have been previously considered by other top ranked journals and for which the previous reviewers' comments and the appropriate responses can be provided. Authors should include relevant information related to previous peer review in their cover l…
Source ↗Publisher website ·- Preprints Preprints
Preprints can be shared anywhere at any time; sharing on a preprint server will not count as prior publication. Model summary
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- ISSN
- 2666-6375
- Electronic ISSN
- 2666-6367
- Society / sponsor
- American Society for Transplantation and Cellular Therapy
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Transplantation and Cellular Therapy
What CAS zone is Transplantation and Cellular Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Transplantation and Cellular Therapy is in Zone 3 of Medicine, and in Zone 3 of the minor category Hematology / Immunology / Transplantation. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Transplantation and Cellular Therapy?
The latest impact factor listed by LetPub is 4.12; CiteScore 8.1.
How long does peer review take at Transplantation and Cellular Therapy?
Based on the dates recorded on 101 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 79 days (interquartile range 50–107 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Transplantation and Cellular Therapy?
According to the journal's author guidelines: Abstract: 250–500 words; Manuscript length: ≤ 1,200 words; Reference style: AMA; First submission: Free format: the journal's layout is not required; Highlights: Required; Graphical abstract: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Transplantation and Cellular Therapy based?
Of the 100 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (81), Germany (6) and Canada (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Transplantation and Cellular Therapy?
According to LetPub and DOAJ records, Transplantation and Cellular Therapy is indexed in SCIE and Scopus. The journal's website also lists PubMed; that list has not been checked against each database.
Is Transplantation and Cellular Therapy open access, and what is the APC?
Transplantation and Cellular Therapy is a fully open-access journal. APC about USD 4,000.
Sources and updates
The facts on this page come from LetPub, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .